Abbotts, R., Topper, M. J., Biondi, C., Fontaine, D., Goswami, R., Stojanovic, L., Choi,
E. Y., McLaughlin, L., Kogan, A. A., Xia, L., et al. (2019). DNA methyltransferase
inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and
ionizing radiation, Proc Natl Acad Sci U S A, 116, 22609-22618.
Abecasis, G. R., Auton, A., Brooks, L. D., DePristo, M. A., Durbin, R. M., Handsaker,
R. E., Kang, H. M., Marth, G. T. and McVean, G. A. (2012). An integrated map of
genetic variation from 1,092 human genomes, Nature, 491, 56-65.
Abou Tayoun, A. N., Pesaran, T., DiStefano, M. T., Oza, A., Rehm, H. L., Biesecker, L.
G. and Harrison, S. M. (2018). Recommendations for interpreting the loss of function
PVS1 ACMG/AMP variant criterion, Hum Mutat, 39, 1517-1524.
Alexandrov, L. B., Kim, J., Haradhvala, N. J., Huang, M. N., Tian Ng, A. W., Wu, Y.,
Boot, A., Covington, K. R., Gordenin, D. A., Bergstrom, E. N., et al. (2020). The
repertoire of mutational signatures in human cancer, Nature, 578, 94-101.
Benson, A. B., D'Angelica, M. I., Abbott, D. E., Anaya, D. A., Anders, R., Are, C.,
Bachini, M., Borad, M., Brown, D., Burgoyne, A., et al. (2021). Hepatobiliary Cancers,
Version 2.2021, NCCN Clinical Practice Guidelines in Oncology, J Natl Compr Canc
Netw, 19, 541-565.
Bertuccio, P., Malvezzi, M., Carioli, G., Hashim, D., Boffetta, P., El-Serag, H. B., La
Vecchia, C. and Negri, E. (2019). Global trends in mortality from intrahepatic and
extrahepatic cholangiocarcinoma, J Hepatol, 71, 104-114.
Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. (1999). J
Natl Cancer Inst. 91, 1310-1316.
Brosens, L. A., Keller, J. J., Offerhaus, G. J., Goggins, M. and Giardiello, F. M. (2005)
Prevention and management of duodenal polyps in familial adenomatous polyposis,
Gut, 54, 1034-1043.
50
Buys, S. S., Sandbach, J. F., Gammon, A., Patel, G., Kidd, J., Brown, K. L., Sharma, L.,
Saam, J., Lancaster, J. and Daly, M. B. (2017). A study of over 35,000 women with
breast cancer tested with a 25-gene panel of hereditary cancer genes, Cancer, 123, 17211730.
Cameron, D. L., Jacobs, N., Roepman, P., Priestley, P., Cuppen, E. and Papenfuss, A. T.
(2021). VIRUSBreakend: Viral Integration Recognition Using Single Breakends,
Bioinformatics. 37, 3115-3119
Cameron, D. L., Schröder, J., Penington, J. S., Do, H., Molania, R., Dobrovic, A.,
Speed, T. P. and Papenfuss, A. T. (2017). GRIDSS: sensitive and specific genomic
rearrangement detection using positional de Bruijn graph assembly, Genome Res, 27,
2050-2060.
Casolino, R., Paiella, S., Azzolina, D., Beer, P. A., Corbo, V., Lorenzoni, G., Gregori,
D., Golan, T., Braconi, C., Froeling, F. E. M., et al. (2021). Homologous Recombination
Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis, J
Clin Oncol, 39, 2617-2631.
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A.,
Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017). Rucaparib
maintenance treatment for recurrent ovarian carcinoma after response to platinum
therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial,
Lancet, 390, 1949-1961.
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O.,
Agarwal, N., Olmos, D., et al. (2020). Olaparib for Metastatic Castration-Resistant
Prostate Cancer, N Engl J Med, 382, 2091-2102.
DePristo, M. A., Banks, E., Poplin, R., Garimella, K. V., Maguire, J. R., Hartl, C.,
Philippakis, A. A., del Angel, G., Rivas, M. A., Hanna, M., et al. (2011). A framework
for variation discovery and genotyping using next-generation DNA sequencing data,
Nat Genet, 43, 491-498.
Dinarvand, P., Davaro, E. P., Doan, J. V., Ising, M. E., Evans, N. R., Phillips, N. J., Lai,
51
J. and Guzman, M. A. (2019). Familial Adenomatous Polyposis Syndrome: An Update
and Review of Extraintestinal Manifestations, Arch Pathol Lab Med, 143, 1382-1398.
Ebata, N., Fujita, M., Sasagawa, S., Maejima, K., Okawa, Y., Hatanaka, Y., Mitsuhashi,
T., Oosawa-Tatsuguchi, A., Tanaka, H., Miyano, S., et al. (2021). Molecular
Classification and Tumor Microenvironment Characterization of Gallbladder Cancer by
Comprehensive Genomic and Transcriptomic Analysis, Cancers, 13. 733
Eckel, F., Brunner, T. and Jelic, S. (2011). Biliary cancer: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 22, 40-44.
Fujimoto, A., Furuta, M., Shiraishi, Y., Gotoh, K., Kawakami, Y., Arihiro, K.,
Nakamura, T., Ueno, M., Ariizumi, S., Nguyen, H. H., et al. (2015). Whole-genome
mutational landscape of liver cancers displaying biliary phenotype reveals hepatitis
impact and molecular diversity, Nat Commun, 6, 6120.
Fujimoto, A., Furuta, M., Totoki, Y., Tsunoda, T., Kato, M., Shiraishi, Y., Tanaka, H.,
Taniguchi, H., Kawakami, Y., Ueno, M., et al. (2016). Whole-genome mutational
landscape and characterization of noncoding and structural mutations in liver cancer,
Nat Genet, 48, 500-509.
Golan, T., Raitses-Gurevich, M., Kelley, R. K., Bocobo, A. G., Borgida, A., Shroff, R.
T., Holter, S., Gallinger, S., Ahn, D. H., Aderka, D., et al. (2017). Overall Survival and
Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter
Retrospective Study, Oncologist, 22, 804-810.
Hirata, M., Kamatani, Y., Nagai, A., Kiyohara, Y., Ninomiya, T., Tamakoshi, A.,
Yamagata, Z., Kubo, M., Muto, K., Mushiroda, T., et al. (2017). Cross-sectional analysis
of BioBank Japan clinical data: A large cohort of 200,000 patients with 47 common
diseases, J Epidemiol, 27, S9-S21.
Hoppe, M. M., Sundar, R., Tan, D. S. P. and Jeyasekharan, A. D. (2018) Biomarkers for
Homologous Recombination Deficiency in Cancer, J Natl Cancer Inst, 110, 704-713.
Knudsen, A. L., Bisgaard, M. L. and Bülow, S. (2003). Attenuated familial adenomatous
52
polyposis (AFAP). A review of the literature, Fam Cancer, 2, 43-55.
Koshiol, J., Gao, Y. T., Dean, M., Egner, P., Nepal, C., Jones, K., Wang, B., Rashid, A.,
Luo, W., Van Dyke, A. L., et al. (2017). Association of Aflatoxin and Gallbladder
Cancer', Gastroenterology, 153, 488-494.e1.
Li, H. and Durbin, R. (2009). Fast and accurate short read alignment with BurrowsWheeler transform, Bioinformatics, 25, 1754-1760.
Lin, J., Cao, Y., Yang, X., Li, G., Shi, Y., Wang, D., Long, J., Song, Y., Mao, J., Xie, F.,
et al. (2021). Mutational spectrum and precision oncology for biliary tract carcinoma,
Theranostics, 11, 4585-4598.
Lord, C. J. and Ashworth, A. (2016). BRCAness revisited, Nat Rev Cancer, 16, 110120.
Maxwell, K. N., Wubbenhorst, B., Wenz, B. M., De Sloover, D., Pluta, J., Emery, L.,
Barrett, A., Kraya, A. A., Anastopoulos, I. N., Yu, S., et al. (2017). BRCA locus-specific
loss of heterozygosity in germline BRCA1 and BRCA2 carriers, Nat Commun, 8, 319.
Maynard, H., Stadler, Z. K., Berger, M. F., Solit, D. B., Ly, M., Lowery, M. A.,
Mandelker, D., Zhang, L., Jordan, E., El Dika, I., et al. (2020). Germline alterations in
patients with biliary tract cancers: A spectrum of significant and previously
underappreciated findings, Cancer, 126, 1995-2002.
Miller, D. T., Lee, K., Chung, W. K., Gordon, A. S., Herman, G. E., Klein, T. E.,
Stewart, D. R., Amendola, L. M., Adelman, K., Bale, S. J., et al. (2021). ACMG SF v3.0
list for reporting of secondary findings in clinical exome and genome sequencing: a
policy statement of the American College of Medical Genetics and Genomics (ACMG),
Genet Med, 23, 1381-1390.
Mizukami, K., Iwasaki, Y., Kawakami, E., Hirata, M., Kamatani, Y., Matsuda, K., Endo,
M., Sugano, K., Yoshida, T., Murakami, Y., et al. (2020). Genetic characterization of
pancreatic cancer patients and prediction of carrier status of germline pathogenic
variants in cancer-predisposing genes, EBioMedicine, 60, 103033.
53
Momozawa, Y., Akiyama, M., Kamatani, Y., Arakawa, S., Yasuda, M., Yoshida, S.,
Oshima, Y., Mori, R., Tanaka, K., Mori, K., et al. (2016). Low-frequency coding
variants in CETP and CFB are associated with susceptibility of exudative age-related
macular degeneration in the Japanese population, Hum Mol Genet, 25, 5027-5034.
Momozawa, Y., Iwasaki, Y., Hirata, M., Liu, X., Kamatani, Y., Takahashi, A., Sugano,
K., Yoshida, T., Murakami, Y., Matsuda, K., et al. (2020). Germline Pathogenic Variants
in 7636 Japanese Patients With Prostate Cancer and 12 366 Controls, J Natl Cancer Inst,
112, 369-376.
Momozawa, Y., Iwasaki, Y., Parsons, M. T., Kamatani, Y., Takahashi, A., Tamura, C.,
Katagiri, T., Yoshida, T., Nakamura, S., Sugano, K.,et al. (2018). Germline pathogenic
variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls, Nat
Commun, 9, 4083.
Momozawa, Y., Sasai, R., Usui, Y., Shiraishi, K., Iwasaki, Y., Taniyama, Y., Parsons, M.
T., Mizukami, K., Sekine, Y., Hirata, M., et al. (2022). Expansion of Cancer Risk Profile
for BRCA1 and BRCA2 Pathogenic Variants, JAMA Oncol, 8, 871-878.
Nagai, A., Hirata, M., Kamatani, Y., Muto, K., Matsuda, K., Kiyohara, Y., Ninomiya, T.,
Tamakoshi, A., Yamagata, Z., Mushiroda, T., et al. (2017). Overview of the BioBank
Japan Project: Study design and profile, J Epidemiol, 27, S2-S8.
Nagase, H., Miyoshi, Y., Horii, A., Aoki, T., Ogawa, M., Utsunomiya, J., Baba, S.,
Sasazuki, T. and Nakamura, Y. (1992). Correlation between the location of germ-line
mutations in the APC gene and the number of colorectal polyps in familial adenomatous
polyposis patients, Cancer Res, 52, 4055-4057.
Nguyen, L., J, W. M. M., Van Hoeck, A. and Cuppen, E. (2020). Pan-cancer landscape
of homologous recombination deficiency, Nat Commun, 11, 5584.
Osorio, A., de la Hoya, M., Rodríguez-López, R., Martínez-Ramírez, A., Cazorla, A.,
Granizo, J. J., Esteller, M., Rivas, C., Caldés, T. and Benítez, J. (2002). Loss of
heterozygosity analysis at the BRCA loci in tumor samples from patients with familial
54
breast cancer', Int J Cancer, 99, 305-309.
Palmer, W. C. and Patel, T. (2012). Are common factors involved in the pathogenesis of
primary liver cancers? A meta-analysis of risk factors for intrahepatic
cholangiocarcinoma, J Hepatol, 57, 69-76.
Park, W., Chen, J., Chou, J. F., Varghese, A. M., Yu, K. H., Wong, W., Capanu, M.,
Balachandran, V., McIntyre, C. A., El Dika, I., et al. (2020). Genomic Methods Identify
Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize
Treatment Selection', Clin Cancer Res, 26, 3239-3247.
Pearl, L. H., Schierz, A. C., Ward, S. E., Al-Lazikani, B. and Pearl, F. M. Therapeutic
opportunities within the DNA damage response, Nat Rev Cancer, 15, 166-180.
Poell, J. B., Mendeville, M., Sie, D., Brink, A., Brakenhoff, R. H. and Ylstra, B. ACE:
absolute copy number estimation from low-coverage whole-genome sequencing data,
Bioinformatics, 35, 2847-2849.
Priestley, P., Baber, J., Lolkema, M. P., Steeghs, N., de Bruijn, E., Shale, C.,
Duyvesteyn, K., Haidari, S., van Hoeck, A., Onstenk, W., et al. (2019). Pan-cancer
whole-genome analyses of metastatic solid tumours, Nature, 575, 210-216.
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R.,
Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019). Olaparib plus
Bevacizumab as First-Line Maintenance in Ovarian Cancer, N Engl J Med, 381, 24162428.
Rozen, S. and Skaletsky, H. (2000). Primer3 on the WWW for general users and for
biologist programmers, Methods Mol Biol, 132, 365-386.
Scheinin, I., Sie, D., Bengtsson, H., van de Wiel, M. A., Olshen, A. B., van Thuijl, H. F.,
van Essen, H. F., Eijk, P. P., Rustenburg, F., Meijer, G. A., et al. (2014). DNA copy
number analysis of fresh and formalin-fixed specimens by shallow whole-genome
sequencing with identification and exclusion of problematic regions in the genome
assembly, Genome Res, 24, 2022-2032.
55
Telli, M. L., Jensen, K. C., Vinayak, S., Kurian, A. W., Lipson, J. A., Flaherty, P. J.,
Timms, K., Abkevich, V., Schackmann, E. A., Wapnir, I. L., et al. (2015). Phase II Study
of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative
and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based
Measure of Genomic Instability: PrECOG 0105, J Clin Oncol, 33, 1895-1901.
Therkildsen, C., Jensen, L. H., Rasmussen, M. and Bernstein, I. (2021). An Update on
Immune Checkpoint Therapy for the Treatment of Lynch Syndrome, Clin Exp
Gastroenterol, 14, 181-197.
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A.,
Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010). Cisplatin plus
gemcitabine versus gemcitabine for biliary tract cancer, N Engl J Med, 362, 1273-1281.
van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M,
Mehra N. (2021). Homologous Recombination Repair Deficiency and Implications for
Tumor Immunogenicity. Cancers (Basel). 13, 2249.
Wang, S., Li, H., Song, M., Tao, Z., Wu, T., He, Z., Zhao, X., Wu, K. and Liu, X. S.
(2021). Copy number signature analysis tool and its application in prostate cancer
reveals distinct mutational processes and clinical outcomes, PLoS Genet, 17, e1009557.
Wardell, C. P., Fujita, M., Yamada, T., Simbolo, M., Fassan, M., Karlic, R., Polak, P.,
Kim, J., Hatanaka, Y., Maejima, K.,et al. (2018). Genomic characterization of biliary
tract cancers identifies driver genes and predisposing mutations, J Hepatol, 68, 959-969.
Win, A. K., Lindor, N. M., Young, J. P., Macrae, F. A., Young, G. P., Williamson, E.,
Parry, S., Goldblatt, J., Lipton, L., Winship, I., et al. (2012). Risks of primary
extracolonic cancers following colorectal cancer in lynch syndrome, J Natl Cancer Inst,
104, 1363-1372.
Wong, K., Serafi, S. W., Bhatia, A. S., Ibarra, I. and Allen, E. A. (2016). Melanoma with
gastric metastases, J Community Hosp Intern Med Perspect. 6, 31972.
56
Wong, W., Lowery, M. A., Berger, M. F., Kemel, Y., Taylor, B., Zehir, A., Srinivasan, P.,
Bandlamudi, C., Chou, J., Capanu, M., et al. (2019). Ampullary cancer: Evaluation of
somatic and germline genetic alterations and association with clinical outcomes, Cancer,
125, 1441-1448.
57
...
論文の公開元へ
